Trial site
Retinal Consultants Medical Group
Sacramento, California 95841, United StatesNot linked to an institution yet
- 18running trials
- 6closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 28 trials
- Phase 37 trials
- Phase 1/24 trials
- Phase 11 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting13 trials
- Completed5 trials
- Recruiting5 trials
- Terminated1 trial
- Lead sponsor
- Boehringer Ingelheim4 trials
- Genentech, Inc.4 trials
- 4D Molecular Therapeutics2 trials
- EyePoint Pharmaceuticals, Inc.2 trials
- Annexon, Inc.1 trial
- and 11 more
Running trials
Recruiting
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
NCT07553429· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Phase 1 Study of C.001 in Retinal Degeneration
NCT07594236· Phase 1· Cellio Therapeutics Inc· Source
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Contact: Study Coordinator
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Active, not recruiting
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731· Phase 3· Stealth BioTherapeutics Inc.· Source
Recruiting
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
NCT05956626· Phase 2/3· Ocugen· Source
Active, not recruiting
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458· Phase 1/2· Perceive Biotherapeutics, Inc.· Source
Recruiting
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114· Phase 2· Genentech, Inc.· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
NCT05300724· Genentech, Inc.· Source
Active, not recruiting
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102· Phase 4· Genentech, Inc.· Source
Recruiting
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270· Phase 1/2· 4D Molecular Therapeutics· Source
Contact: Rashin Sedighi
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error